Israel's Teva puts foreigner in line for CEO's job; Vertex wins expanded label for Kalydeco
→ Israel’s Teva is reportedly taking a hard look at a foreigner for its next CEO, sparking a patriotic row.
→ The FDA has approved Vertex’s Kalydeco for use in people with cystic fibrosis (CF) ages 2 and older who have one of 23 residual function mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. As a result, the Boston biotech bumped up its revenue projections for the year to $770 million.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.